All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
Emmanuel BachyDuring the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Emmanuel Bachy, Hospices Civils de Lyon, Lyon, FR. We asked, How can we better treat patients with early-relapsing follicular lymphoma?
How can we better treat patients with early-relapsing follicular lymphoma?
Emmanuel Bachy starts by stating that challenges remain in 2020 for treating patients with follicular lymphoma. Patients who relapse in the first 1–2 years after immunotherapy have a 5-year survival of only 40–50%. He goes on to discuss prognostic factors that are available both for prognosis and monitoring after treatment.
Bachy then turns his focus to therapeutic agents. The current available treatments are discussed, with respect to the age and frailty of the patients.